TRANSLATE

The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

FDA accepts a Biologics License Application for obe-cel in patients with R/R B-ALL

By Quintina Dawson

Share:

Jan 25, 2024

Learning objective: After reading this article, learners will be able to cite a new clinical development in ALL


On January 22, 2024, the U.S. Food and Drug Administration (FDA) accepted a Biologics License Application for obecabtagene autoleucel (obe-cel), a novel autologous CD19 CAR T-cell therapy designed with a fast off-rate CD19 binding domain to improve persistence and reduce toxicities, for the treatment of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia. This decision was based on data from the pivotal phase II FELIX study (NCT04404660).1,2

The ALL hub previously reported the efficacy and safety outcomes from the FELIX study. Updated data was presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. A total of 127 patients were infused with obe-cel. By the data cut-off on September 13, 2023,

  • 74% of patients with morphological disease (n = 98) achieved a complete remission/complete response with incomplete count recovery rate;
  • 95% of responders were measurable residual disease-negative;
  • high complete response/complete response with incomplete count recovery rates were seen across all subgroups, including those with high-burden and extramedullary disease;
  • the 12-month event-free survival rate was 50%; and
  • obe-cel demonstrated long-term persistence and a favorable safety profile, with low rates of Grade ≥3 cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome reported.

For this indication, obe-cel previously received Orphan Drug Designation and Regenerative Medicine Advanced Therapy designation by the FDA, as well as Orphan Medical Product Designation and Priority Medicines designation by the European Medicines Agency (EMA).

References

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content